BioNTech, Autolus strike wide-ranging licensing and manufacturing deal for CAR-T therapies
BioNTech is enlisting CAR-T biotech Autolus Therapeutics on a partnership aimed at pushing both of their CAR-T programs toward commercialization, with an eye on its new partner’s programs as well as manufacturing capabilities.
As part of the wide-ranging agreement, BioNTech will purchase $200 million of Autolus’ shares in a private placement, plus dish out a cash payment of $50 million.
In exchange, BioNTech will receive up to mid-single digit royalty on net sales of Autolus’ lead CD19 therapy, obe-cel, which is now under review at the FDA for relapsed/refractory adult B cell acute lymphoblastic leukemia. It will also have an option to get a profit share on Autolus’ other CAR-T therapies, AUTO1/22 and AUTO6NG, in any cancer type, if it co-supports development and commercialization. Autolus will be eligible to receive an option exercise fee, milestone payments and co-funding of development expenses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.